Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MIST News 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ (etripamil) nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT)—a rapid heart rhythm disturbance that can be frightening, disruptive, and costly when it sends patients to emergency care. GlobeNewswire Yet in classic biotech fashion, the stock market’s reaction has been anything but simple. Despite the “yes” from regulators, MIST shares saw sharp volatility into the weekend, and investors
15 December 2025
·
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage cardiovascular company. GlobeNewswire+1 The stock action was anything but calm. MIST closed at $2.41 on Dec. 12, down 18.31%, after swinging through a wide intraday range and printing exceptionally heavy volume. After-hours trading showed a modest rebound. StockAnalysis Below is a detailed breakdown of the latest Milestone Pharmaceuticals news, this week’s trading story, forecasts and analyst targets, and the week-ahead
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Updated: December 13, 2025 Milestone Pharmaceuticals Inc. (Nasdaq: MIST) just crossed the line that separates “clinical-stage story stock” from “commercial execution stock.” Late Friday, the company announced FDA approval of CARDAMYST™ (etripamil)—a self-administered nasal spray for adults to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. GlobeNewswire And because markets love drama, MIST didn’t celebrate with a calm, rational repricing. Instead, the stock spent the week building into the decision, then delivered a violent rollercoaster session into Friday’s close—before the after-hours approval news hit. Now investors head into next week with a new reality: the regulatory
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Updated: December 12, 2025Company: Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company’s lead program, CARDAMYST™ (etripamil) nasal spray , aimed at treating paroxysmal supraventricular tachycardia (PSVT) . The regulatory catalyst arrives after a volatile year that included an FDA Complete Response Letter (CRL) earlier in 2025, followed by the FDA’s acceptance of Milestone’s resubmission and a new target action date set for mid-December.GlobeNewswire+ 2GlobeNewswire+ 2 In the market, MIST shares closed at $2.95 on Dec. 11
12 December 2025
·

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop